Francesca Usberti

This inventor holds 10 USPTO granted patents and 14 published patent applications, plus 6 CIPO patents and 6 EPO patents. Top assignee: Chiesi Farmaceutici S.p.a.. Active years: 2018-2026.

USPTO Granted Patents = 10 (Patent Applications = 14)

% Patents Active = 100.0

CIPO Patents = 6 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 13)

Average Co-Inventor Count = 3.7

ph-index = 2

Forward Citations = 16(Granted Patents)

Company Filing History:

10 out of 341

Chiesi Farmaceutici S.p.a.

patents

Years Active: 2018-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12616654 - Stainless steel can for pressurised metered dose inhalers (2026-05-05),

2. 12357568 - Aerosol formulation for COPD (2025-07-15),

3. 11590074 - Aerosol formulation for COPD (2023-02-28),

4. 11389401 - Combination therapy for COPD (2022-07-19),

5. 10806701 - Aerosol formulation for COPD (2020-10-20),

6. 10617669 - Stable pressurized aerosol solution composition of glycopyrronium bromide and formoterol combination (2020-04-14),

7. 10617638 - Stable pressurized aerosol solution composition of glycopyrronium bromide and formoterol combination (2020-04-14),

8. 10596149 - Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination (2020-03-24),

9. 10596113 - Stable pressurized aerosol solution composition of glycopyrronium bromide and formoterol combination (2020-03-24),

10. 10159645 - Combination therapy for COPD (2018-12-25),

Title: Francesca Usberti: Innovator in Respiratory Solutions

Introduction

Francesca Usberti is a prominent inventor based in Parma, Italy. She has made significant contributions to the field of respiratory medicine, particularly in the development of aerosol formulations for chronic obstructive pulmonary disease (COPD). With a total of 10 patents to her name, Usberti's work is vital for improving patient care in respiratory conditions.

Latest Patents

Among her latest patents is an aerosol formulation specifically designed for COPD. This stable aerosol solution comprises glycopyrronium bromide, which is beneficial for administration to patients suffering from COPD and other respiratory conditions. This innovative formulation aims to enhance the delivery and effectiveness of treatment for individuals with respiratory challenges.

Career Highlights

Francesca Usberti has established herself as a key figure in her field through her work at Chiesi Farmaceutici S.p.a. Her dedication to research and development has led to advancements that significantly impact patient outcomes. Her expertise in aerosol formulations has positioned her as a leader in respiratory therapy innovations.

Collaborations

Usberti collaborates with notable colleagues, including Sauro Bonelli and Enrico Zambelli. These partnerships foster a dynamic environment for innovation and contribute to the success of their projects in respiratory medicine.

Conclusion

Francesca Usberti's contributions to aerosol formulations for COPD exemplify her commitment to advancing respiratory health. Her innovative work continues to pave the way for improved treatments and better patient care.